Skip to content
DataLookout
Menu

NCT07222800

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 372 → 401 locations
  2. Minor Trial sites expanded: 348 → 372 locations
  3. Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
    • Trial sites expanded: 308 → 348 locations
    • Primary completion moved earlier from Mar 29, 2030 to Feb 23, 2030
    • Study completion date: Aug 1, 2031 to Aug 17, 2031
    • Secondary endpoints: details revised at 3 of 14 entries
  4. Minor Trial sites expanded: 285 → 308 locationsv9
  5. Minor Trial sites expanded: 259 → 285 locationsv8
  6. Minor Trial sites expanded: 228 → 259 locationsv7
  7. Minor Trial sites expanded: 156 → 228 locationsv6
  8. Minor Trial sites expanded: 115 → 156 locationsv5
  9. Minor Trial sites expanded: 16 → 115 locations
    • Study title expanded, about 1 word
    v4
  10. Notable Eligibility criteria expanded, about 7 wordsv3
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 16
    • Start date changed from estimate of Dec 12, 2025 to Dec 11, 2025
    • Secondary endpoints revised (14)
    v2
  12. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)
Timeframe: Approximately 4 years
Overall survival (OS)
Timeframe: Approximately 4 years

Secondary (14)

PFS per RECIST 1.1 by investigator assessment
Objective Response Rate (ORR) by BICR
Objective Response Rate (ORR) by investigator
Duration of Response (DOR) by BICR
DOR by investigator
Show 9 moreShow less
PFS2 (PFS after next-line therapy) by investigator
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Clinical Laboratory Abnormalities
Pharmacokinetics (PK): Serum concentration of PF-08634404
Immunogenicity: Incidence of positive Anti-Drug Antibody (ADA)
Mean scores and Change from baseline in the global health status/quality of life (QoL) score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Mean score change from baseline in participant reported function and symptoms scales per EORTC QLQ-CR29
Time to definitive deterioration (TTdD) in the global health status/QoL score on the EORTC QLQ-C30
Time to definitive deterioration (TTdD) in participant reported function and symptoms per EORTC QLQ-CR29

Arms and interventions

PF-08634404 + ChemotherapyExperimental

Participants will receive PF-08634404 intravenously (IV) in combination with Chemotherapy.

Bevacizumab + ChemotherapyActive comparator

Participants will receive bevacizumab IV in combination with Chemotherapy.

Drugs: PF-08634404, Chemotherapy

Biologicals: Bevacizumab

Sites

401 sites in 20 countries

United States 272, China 24, Spain 13, Japan 11, Germany 9, France 7, Italy 7, South Korea 7, Brazil 6, Taiwan 6, Argentina 5, Australia 5, Israel 5, Poland 5, Belgium 4, Canada 4, Denmark 4, India 3, Puerto Rico 3, Netherlands 1